Lixte Biotechnology Holdings Stock Today
| LIXT Stock | USD 1.34 0.04 3.08% |
PerformanceVery Weak
| Odds Of DistressVery High
|
Lixte Biotechnology is selling for under 1.34 as of the 24th of March 2025; that is 3.08 percent increase since the beginning of the trading day. The stock's last reported lowest price was 1.25. Lixte Biotechnology has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 24th of December 2024 and ending today, the 24th of March 2025. Click here to learn more.
Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company was founded in 2005 and is based in Pasadena, California. The company has 2.68 M outstanding shares of which 55.52 K shares are now shorted by private and institutional investors with about 0.3 trading days to cover. More on Lixte Biotechnology Holdings
Moving against Lixte Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Lixte Stock Highlights
| CEO President | Bastiaan MSc |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
| Financial Strength | |
Lixte Biotechnology Holdings (LIXT) is traded on NASDAQ Exchange in USA. It is located in 680 East Colorado Boulevard, Pasadena, CA, United States, 91101 and employs 3 people. Lixte Biotechnology is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 3.49 M. Lixte Biotechnology conducts business under Biotechnology sector and is part of Health Care industry. The entity has 2.68 M outstanding shares of which 55.52 K shares are now shorted by private and institutional investors with about 0.3 trading days to cover.
Lixte Biotechnology Holdings currently holds about 7.74 M in cash with (4.29 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.47.
Check Lixte Biotechnology Probability Of Bankruptcy
Ownership AllocationLixte Biotechnology Holdings secures 18.71 % of its outstanding shares held by insiders and 15.75 % owned by institutional investors.
Check Lixte Ownership Details
Lixte Biotechnology Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Lixte Biotechnology market risk premium is the additional return an investor will receive from holding Lixte Biotechnology long position in a well-diversified portfolio.
| Risk Adjusted Performance | (0.06) | |||
| Jensen Alpha | (0.51) | |||
| Total Risk Alpha | (0.27) | |||
| Treynor Ratio | (0.94) |
Lixte Stock Against Markets
Lixte Biotechnology Corporate Management
| Johannes MD | Chief Officer | Profile | |
| James MD | Chief Officer | Profile | |
| Robert Weingarten | VP CFO | Profile | |
| Eric JD | VP COO | Profile | |
| John MD | President, Founder | Profile |
Additional Tools for Lixte Stock Analysis
When running Lixte Biotechnology's price analysis, check to measure Lixte Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lixte Biotechnology is operating at the current time. Most of Lixte Biotechnology's value examination focuses on studying past and present price action to predict the probability of Lixte Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lixte Biotechnology's price. Additionally, you may evaluate how the addition of Lixte Biotechnology to your portfolios can decrease your overall portfolio volatility.